Statera Biopharma, Inc. announced the pricing of its underwritten public offering of approximately 10,843,721 units, at a price to the public of $0.45 per Unit and approximately 1,716,666 pre-funded units, at a price to the public of $0.44 per Pre-Funded Unit, for aggregate gross proceeds of approximately $5.7 million, prior to deducting underwriting discounts, commissions, and other estimated offering expenses.
March 22, 2022
· 6 min read